MX2021001507A - Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer. - Google Patents

Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.

Info

Publication number
MX2021001507A
MX2021001507A MX2021001507A MX2021001507A MX2021001507A MX 2021001507 A MX2021001507 A MX 2021001507A MX 2021001507 A MX2021001507 A MX 2021001507A MX 2021001507 A MX2021001507 A MX 2021001507A MX 2021001507 A MX2021001507 A MX 2021001507A
Authority
MX
Mexico
Prior art keywords
diagnostic
disease
amino acid
alzheimer
drug
Prior art date
Application number
MX2021001507A
Other languages
English (en)
Inventor
Atsushi Ono
Yasuhiro Teranishi
Masanori Kusumoto
Masakazu Hashimoto
Shoji Kashiwabara
Maki Hashimoto
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2021001507A publication Critical patent/MX2021001507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

La presente invención provee un polipéptido que consiste en cualquiera de las siguientes secuencias de aminoácidos y es útil para la determinación de la enfermedad de Alzheimer: (1) la secuencia de aminoácidos mostrada en SEQ ID NO: 1; y (2) una secuencia de aminoácidos que resulta de la sustitución, deleción, adición o inserción de uno a muchos aminoácidos en la secuencia de aminoácidos mostrada en SEQ ID NO: 1.
MX2021001507A 2018-08-07 2019-08-06 Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer. MX2021001507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018148924 2018-08-07
PCT/JP2019/030904 WO2020032027A1 (ja) 2018-08-07 2019-08-06 アルツハイマー病の判定薬および判定方法

Publications (1)

Publication Number Publication Date
MX2021001507A true MX2021001507A (es) 2021-04-28

Family

ID=69413505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001507A MX2021001507A (es) 2018-08-07 2019-08-06 Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.

Country Status (10)

Country Link
US (1) US20210165002A1 (es)
EP (1) EP3835424A4 (es)
JP (2) JP7470041B2 (es)
KR (1) KR20210041035A (es)
CN (1) CN112567039A (es)
AU (1) AU2019318888A1 (es)
CA (1) CA3108440A1 (es)
MX (1) MX2021001507A (es)
TW (1) TW202035438A (es)
WO (1) WO2020032027A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163613A1 (en) * 2020-02-13 2021-08-19 Cognition Therapeutics, Inc. Method of decreasing amyloid beta monomer levels in patients with cognitive decline
WO2023036105A1 (zh) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
KR101647519B1 (ko) 2008-07-08 2016-08-10 스미토모 베이클리트 컴퍼니 리미티드 포지티브형 감광성 수지 조성물, 경화막, 보호막, 절연막 및 그것들을 이용한 반도체 장치, 표시체 장치
WO2010048497A1 (en) * 2008-10-24 2010-04-29 Genizon Biosciences Inc. Genetic profile of the markers associated with alzheimer's disease
JP5894085B2 (ja) * 2010-12-28 2016-03-23 大日本住友製薬株式会社 アルツハイマー病の診断薬及び診断方法
WO2014138262A1 (en) 2013-03-05 2014-09-12 Xiant Technologies, Inc. Photon modulation management system
WO2021157634A1 (ja) * 2020-02-05 2021-08-12 大日本住友製薬株式会社 タウオパチーおよび認知症関連疾患の判定薬および判定方法

Also Published As

Publication number Publication date
TW202035438A (zh) 2020-10-01
EP3835424A1 (en) 2021-06-16
JP7470041B2 (ja) 2024-04-17
AU2019318888A1 (en) 2021-03-18
EP3835424A4 (en) 2022-05-04
JP2024054181A (ja) 2024-04-16
WO2020032027A1 (ja) 2020-02-13
JPWO2020032027A1 (ja) 2021-09-09
KR20210041035A (ko) 2021-04-14
CA3108440A1 (en) 2020-02-13
US20210165002A1 (en) 2021-06-03
CN112567039A (zh) 2021-03-26

Similar Documents

Publication Publication Date Title
MX2018004938A (es) Vacunas de antigeno ligado a pcrv de p. aeruginosa.
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
PH12017501520A1 (en) Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
PH12017502213A1 (en) Compositions and methods for treating celiac sprue disease
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
EA202190240A1 (ru) Варианты рекомбинантного белка
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
JP2019500414A5 (es)
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
WO2015107363A3 (en) Mycobacterial antigen composition
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
MX2022002433A (es) Análogos de compstatina y sus usos médicos.
DK2289533T3 (da) Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
PH12018500468A1 (en) Fusion protein
BR112022012057A2 (pt) Novos métodos de entrega celular
MX2010005816A (es) Epítopos de péptido de stat3.
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
JP2015129652A5 (es)
MX2020013924A (es) Composicion inmunogena para paratuberculosis.